Interactions of the public and private sectors in drug development: boundaries to protect scientific values while preserving innovation.
Industry, academia, and government have developed highly interwoven relationships in the pursuit of biomedical research. Establishing and maintaining boundaries among the public and private sectors at both the institutional level and the individual level is critical to protect core scientific values, preserve innovation, and allow product development to thrive. This article reviews principles that guide the interactions of these Biomdifferent sectors, sharing principles in place at Eli Lilly and Company as an example.
Cassell
Gail H
GH
Eli Lilly and Company, Indianapolis, IN 46285, USA. G.cassell@Lilly.com
D000046:Academic Medical Centers / Q000191:economics / Q000941:ethics*; D000407:Alabama; D035843:Biomedical Research / Q000941:ethics*; D016265:Conflict of Interest; D003299:Cooperative Behavior; D004059:Diffusion of Innovation; D004341:Drug Evaluation / Q000191:economics / Q000941:ethics*; D004345:Drug Industry / Q000941:ethics*; D033161:Government Regulation; D006801:Humans; D017149:Private Sector / Q000941:ethics; D017150:Public Sector / Q000941:ethics; D015871:Scientific Misconduct; D014481:United States